Telix Pharmaceuticals Ltd
Research Telix Pharmaceuticals Ltd (TLX) on Bullrun: market cap USD 3.96B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTLX
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.96B
- Financial periodFY2025
- RevenueUSD 803.79M
- Revenue growth55.6%
- Net income-USD 7.13M
- Free cash flow-USD 61.07M
- Gross margin53.1%
Valuation Snapshot
latest market cap is USD 3.96B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 803.79M | -USD 7.13M | -USD 61.07M | 53.1% | -0.02 | USD 141.87M | USD 467.11M | USD 415.38M |
| FY2024 | USD 516.55M | USD 33.69M | USD 5.31M | 65.1% | 0.1 | USD 440.00M | USD 360.16M | USD 352.94M |
| FY2023 | USD 332.98M | USD 4.21M | USD 7.16M | 62.9% | 0.01 | USD 84.30M | USD 12.26M | USD 102.65M |
| FY2022 | USD 108.91M | -USD 104.08M | -USD 77.83M | 59.3% | -0.34 | USD 116.33M | USD 10.45M | USD 54.43M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.96B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.54B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.15B | n/a | n/a | n/a |
About Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Telix Pharmaceuticals Ltd's market cap?
Telix Pharmaceuticals Ltd's market capitalization is USD 3.96B.
What does Telix Pharmaceuticals Ltd do?
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.